MedTrace Logo

Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization

NCT07130500 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2026-03-27

No results posted yet for this study

Summary

This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance use disorder who are recently discharged from involuntary hospitalization or are at high risk of future involuntary hospitalization. Participants will be randomized to receive financial incentives for adherence to long-acting injectable medications or to a control group.

Conditions

  • Schizophrenia Disorder
  • Schizoaffective Disorder
  • Bipolar Disorder (BD)
  • Substance Use Disorder (SUD)

Interventions

BEHAVIORAL

Financial incentives for adherence to long-acting injectable medication

This intervention is a randomized controlled trial where patients in the treatment group are offered financial incentives for taking long-acting injectable (LAI) versions of the antipsychotic and substance use disorder medications they need and the control group receives the status quo standard of care.

BEHAVIORAL

Standard of care with monthly surveys

Receives standard outpatient care and incentives for completing monthly surveys.

Sponsors & Collaborators

  • University of Pittsburgh Medical Center

    collaborator OTHER

  • Arnold Ventures

    collaborator OTHER

  • Allegheny County Department of Human Services

    collaborator UNKNOWN

  • Pittsburgh Mercy

    collaborator UNKNOWN

  • Stanford Impact Labs

    collaborator UNKNOWN

  • Federal Reserve Bank of New York

    collaborator UNKNOWN

  • Stanford University

    lead OTHER

Principal Investigators

  • Antoine Douaihy, MD · University of Pittsburgh

  • Valentin Bolotnyy, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2029-03-31
Completion
2030-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07130500 on ClinicalTrials.gov